open access

Vol 65, No 4 (2014)
Postgraduate education
Published online: 2014-08-29
Submitted: 2014-08-29
Accepted: 2014-08-29
Get Citation

Acromegaly — a novel view of the patient. Polish proposals for diagnostic and therapeutic procedures in the light of recent reports

Marek Bolanowski, Marek Ruchała, Wojciech Zgliczyński, Beata Kos-Kudła, Agata Bałdys-Waligórska, Grzegorz Zieliński, Tomasz Bednarczuk, Alicja Hubalewska-Dydejczyk, Grzegorz Kamiński, Bogdan Marek, Jacek Daroszewski, Ryszard Waśko, Andrzej Lewiński
DOI: 10.5603/EP.2014.0045
·
Endokrynologia Polska 2014;65(4):326-331.

open access

Vol 65, No 4 (2014)
Postgraduate education
Published online: 2014-08-29
Submitted: 2014-08-29
Accepted: 2014-08-29

Abstract

is usually delayed and is often associated with the development of various complications causing premature mortality. In patients with hypertension, heart failure, diabetes, and arthropathy that is non-specific for age, attention should be paid to the occurrence of somatic signs of acromegaly. As a screening test, insulin-like growth factor-1 (IGF-1) concentration should be assessed. Further diagnostic and treatment procedures are possible in specialised centres. The first-line therapy is selective transsphenoidal adenomectomy. Patients with a good prognosis related to a surgical removal of the pituitary tumour should be referred only to centres experienced in performing this type of procedure, after pharmacological preparation. Other patients, and those who have not recovered after surgical treatment, should be subjected to long-term pharmacotherapy with long-acting somatostatin analogues. In each case, the complications of acromegaly should be followed-up long-term and actively treated. This proposed new recommendation should be helpful for the management of patients with acromegaly. (Endokrynol Pol 2014; 65 (4): 326–331)

Abstract

is usually delayed and is often associated with the development of various complications causing premature mortality. In patients with hypertension, heart failure, diabetes, and arthropathy that is non-specific for age, attention should be paid to the occurrence of somatic signs of acromegaly. As a screening test, insulin-like growth factor-1 (IGF-1) concentration should be assessed. Further diagnostic and treatment procedures are possible in specialised centres. The first-line therapy is selective transsphenoidal adenomectomy. Patients with a good prognosis related to a surgical removal of the pituitary tumour should be referred only to centres experienced in performing this type of procedure, after pharmacological preparation. Other patients, and those who have not recovered after surgical treatment, should be subjected to long-term pharmacotherapy with long-acting somatostatin analogues. In each case, the complications of acromegaly should be followed-up long-term and actively treated. This proposed new recommendation should be helpful for the management of patients with acromegaly. (Endokrynol Pol 2014; 65 (4): 326–331)

Get Citation

Keywords

acromegaly; diagnosis; therapy; guidelines

About this article
Title

Acromegaly — a novel view of the patient. Polish proposals for diagnostic and therapeutic procedures in the light of recent reports

Journal

Endokrynologia Polska

Issue

Vol 65, No 4 (2014)

Pages

326-331

Published online

2014-08-29

DOI

10.5603/EP.2014.0045

Bibliographic record

Endokrynologia Polska 2014;65(4):326-331.

Keywords

acromegaly
diagnosis
therapy
guidelines

Authors

Marek Bolanowski
Marek Ruchała
Wojciech Zgliczyński
Beata Kos-Kudła
Agata Bałdys-Waligórska
Grzegorz Zieliński
Tomasz Bednarczuk
Alicja Hubalewska-Dydejczyk
Grzegorz Kamiński
Bogdan Marek
Jacek Daroszewski
Ryszard Waśko
Andrzej Lewiński

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl